WebOct 20, 2024 · Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS … WebJun 2, 2024 · DOI: 10.1200/JCO.2024.40.16_suppl.9006 Journal of Clinical Oncology - published online before print June 2, 2024 Amivantamab and lazertinib in patients with …
Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific …
WebAug 2, 2024 · CHRYSALIS, a first-in-human, phase I dose-escalation, and dose-expansion study ( NCT02609776 ), evaluates the efficacy, safety, and pharmacokinetics of amivantamab in patients with advanced NSCLC. WebSep 20, 2024 · At ASCO 2024, Catherine A. Shu, MD, spoke about the CHRYSALIS-2 trial which investigated the use of amivantamab plus lazertinib in patients with EGFR-mutant non–small cell lung cancer following progression on a prior EGFR inhibitor. Catherine A. Shu, MD Clinical director of the Thoracic Medical Oncology Service how many books has andy marino written
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I …
WebSep 7, 2024 · Patients are eligible post- chemo and post-MET TKI (s). Contact: [email protected]. Trial Eligibility Criteria and Locations. Trial ID: NCT02609776. Condition: Non-Small Cell Lung Cancer Intervention: Parallel Assignment Study Type: Interventional. Study Phase: I. Study Sponsor: Janssen Research & Development, LLC … WebTreatment with RYBREVANT ® was evaluated in the CHRYSALIS trial CHRYSALIS is a multicenter, open-label, multicohort study that included 129 adult patients with locally … WebJun 5, 2024 · Initially, Dr Minchom discusses the updated results from CHRYSALIS-2 regarding amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy. The panel then talks about overcoming the resistance to TKIs and cover the latest on Exon 20 … high priestess energy